OPTN Company Profile and Key Details

Q: Who are the executives of OPTN?

Ms. Michele Janis MBAVice President & Acting Chief Financial OfficerMr. Peter K. MillerChief Executive Officer & DirectorMs. Karen E. BrophyChief HR Officer & Vice President of HRMr. Michael F. Marino Esq.Chief Legal Officer & Corporation Sec.Mr. Victor M. ClavelliChief Commercial OfficerDr. Per Gisle Djupesland M.D., Ph.D.Co-Founder & Chief Scientific Officer of OptiNose ASMr. Jonathan NeelyVice President of Investor Relations & Bus. OperationsMr. Paul SpenceChief Commercial OfficerMr. Anthony KrickVice President & Chief Accounting OfficerMs. Helena Kyttari DjupeslandCo-Founder of Optinose AS (Norway) & Co-Chief Executive Officer of Optinose AS (Norway)Mr. John MessinaSenior Vice President of Clinical Devel. & Medical AffairsDr. Ramy A. Mahmoud M.D., M.P.H.Chief Executive Officer & DirectorMr. Anthony J. KrickVice President & Chief Accounting Officer

NASDAQ : OPTN

OptiNose

$9.60

At Close 4:00 PM

Not Actively Trading

68.36

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

OptiNose, Inc. (OPTN) stock remained unchanged at $9.60 a share on NASDAQ. The stock opened at $9.60, fluctuating between $9.60 to $9.60 during the session.

Stock Snapshot

9.6

Prev. Close

97.22M

Market Cap

9.6

Day Low

-4.423963133640553

P/E Ratio

-2.17

EPS (TTM)

-0.19

Cash Flow per Share

9.6

Open

10.13M

Number of Shares

9.6

Day High

62.25%

Free Float in %

-0.77

Book Value

811.06K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 21, 2025	9.60	9.60	9.60	9.60	0
May 20, 2025	9.67	9.72	9.48	9.60	808.75K
May 19, 2025	9.62	9.75	9.50	9.71	56.79K
May 16, 2025	9.44	9.74	9.44	9.69	169.94K
May 15, 2025	9.42	9.58	9.42	9.52	26.96K
May 14, 2025	9.42	9.49	9.42	9.42	15.91K
May 13, 2025	9.45	9.47	9.41	9.45	7.51K
May 12, 2025	9.43	9.43	9.40	9.42	8.52K
May 09, 2025	9.41	9.41	9.38	9.39	8.06K
May 08, 2025	9.39	9.43	9.37	9.39	21.15K
May 07, 2025	9.38	9.43	9.38	9.40	7.27K
May 06, 2025	9.40	9.44	9.38	9.38	22.78K
May 05, 2025	9.38	9.44	9.38	9.42	20.51K
May 02, 2025	9.41	9.45	9.38	9.40	21.19K
May 01, 2025	9.33	9.39	9.33	9.39	12.4K
Apr 30, 2025	9.28	9.37	9.28	9.32	17.59K
Apr 29, 2025	9.32	9.35	9.28	9.32	32.18K
Apr 28, 2025	9.29	9.35	9.25	9.34	25.38K
Apr 25, 2025	9.20	9.30	9.20	9.28	18.76K
Apr 24, 2025	9.18	9.29	9.18	9.26	47.19K

Contact Details

Yardley, PA 19067

United States

https://www.optinose.com 267 364 3500

About Company

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Stock Peers

NBIX

-1.91-1.37%

Neurocrine Biosciences, Inc.$137.65 ITCI

Intra-Cellular Therapies, Inc.$131.87 ANIP

-0.43-0.54%

ANI Pharmaceuticals, Inc.$79.91 LNTH

1.96+3.01%

Lantheus Holdings, Inc.$67.17 PAHC

-0.11-0.21%

Phibro Animal Health Corporation$51.74 SUPN

-0.12-0.23%

Supernus Pharmaceuticals, Inc.$51.18 HROW

0.25+0.53%

Harrow Health, Inc.$47.71 COLL

0.47+1.02%

Collegium Pharmaceutical, Inc.$46.75 INDV

-0.4-1.18%

Indivior Pharmaceuticals Inc$33.46 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98

Company Overview

The stock is currently mid-range between its 52-week high and low $4.82 and $20.02. With a market capitalization of about $97.22 million, OptiNose, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.89). Key stats such as the average daily volume over the past year has been around 119.12 thousand shares, trading with heavier-than-usual volume. Headquartered in Yardley, PA, OptiNose, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Ramy A. Mahmoud, the company employs approximately 127 people and listed since October 13, 2017. OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 1.98%, SMA50 9.68%, SMA200 5.32%). The stock’s 14-day RSI is 72.35 (overbought), while the ATR of 0.15 points to moderate volatility. The stock remains hovering near 52-week lows, trading -52.06% below its high and over 99.38% above its low.

Valuation Metrics

OptiNose, Inc. trades at a P/E ratio of -5.02, slightly below the S&P 500 average, with a price-to-sales ratio of 1.58 and a price-to-book ratio of -1.83 indicating negative book value, which may reflect financial stress. The P/FCF stands at -5.25, also above market averages.

Dividend & Fair Value

OptiNose, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.37. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

OptiNose, Inc. generated EPS of -$2.98 over the past year. Five-year average earnings growth is 44.26%. The latest quarter delivered EPS of -$1.01. The next quarter is forecast at -$0.40. Next year's EPS is expected at $20.24. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $9.00. The high target offers -6.25% upside. The low target suggests -6.25% downside. The mean target is $9.00. This offers -6.25% upside. OptiNose, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2025, missed forecasts by 36.49%. The prior quarter beat by -95.71%. Over the last six quarters, Apple has recorded several small beats. These include -10.0% in March 07, 2024.

Shareholding & Insider Activity

OptiNose, Inc. has 10.13 million shares outstanding. The public float is 6.42 million shares, elevated short interest at 1.61% of float. This equals 142.21 thousand shares. The short ratio is 0.62 days. Institutional investors hold 77.27% of the float. Insiders own 6.34%. Miller Peter K holds 853.38 thousand shares, Clavelli Victor M has 199.96 thousand shares and Goldan Keith A. has 141.73 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, OptiNose generated $70.99M in revenue, or $0.63 per share. Gross margin was 87.27%, operating margin -32.05%, and net profit margin -49.99%. Returns are negative, with ROA at -32.94% and ROE at 40.97%.
On valuation metrics, OptiNose trades at a P/E of -5.02, P/S of 1.58 and P/B of -1.83. Liquidity is tight, with a current ratio of 0.64 and quick ratio of 0.58. Operationally, the company’s inventory turnover is 0.51 and cash conversion cycle is 762.75 days. Debt-to-equity is -2.07, supported by a cash flow-to-debt ratio of -0.15.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, OptiNose posted revenue of $70.99M, down slightly from $76.28M in the prior quarter. Gross profit was $61.95M (margin 87.27%). Operating income was - $22.75M (margin -32.0%). Net income was- $35.48M (EPS - $0.32).
The company ended the quarter with $73.68M in cash and short-term investments, a total debt of $131.75M, and net debt of $58.07M. Total assets were $107.73M, with equity of - $86.61M. Financials further reflected weakness, with operating cash flow of - $20.53M, free cash flow of - $20.86M, and capital expenditures of - $328.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that OptiNose, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.06%, with price expected at $9.99 by June 04, 2025, within a range of $9.90 to $10.09 3-Month Outlook: Projected rise of 123.33%, reaching $21.44 by August 19, 2025, with a range of $20.23 to $22.59. 1-Year Outlook: Projected gain of 65.1%, with price at $15.85 by May 21, 2026, within a range of $0.00 to $21.53.

Key Takeaways

OptiNose, Inc. (NASDAQ:OPTN) shares are up 43.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows OptiNose, Inc. trading at a premium to the broader market with a P/E of -5.02. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $10.00, suggesting 4.17% upside. Our AI forecast model points to short-term strength (4.06% over two weeks), a medium-term rise (123.33% over three months), and a longer-term gain (65.1% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current OptiNose, Inc. (OPTN) stock price?

OptiNose, Inc. (NASDAQ: OPTN) stock price is $9.60 in the last trading session. During the trading session, OPTN stock reached the peak price of $9.60 while $9.60 was the lowest point it dropped to. The percentage change in OPTN stock occurred in the recent session was 0% while the dollar amount for the price change in OPTN stock was $0.00.

OPTN's industry and sector of operation?

The NASDAQ listed OPTN is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. OptiNose, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OPTN?

Ms. Michele Janis MBA
Vice President & Acting Chief Financial Officer
Mr. Peter K. Miller
Chief Executive Officer & Director
Ms. Karen E. Brophy
Chief HR Officer & Vice President of HR
Mr. Michael F. Marino Esq.
Chief Legal Officer & Corporation Sec.
Mr. Victor M. Clavelli
Chief Commercial Officer
Dr. Per Gisle Djupesland M.D., Ph.D.
Co-Founder & Chief Scientific Officer of OptiNose AS
Mr. Jonathan Neely
Vice President of Investor Relations & Bus. Operations
Mr. Paul Spence
Chief Commercial Officer
Mr. Anthony Krick
Vice President & Chief Accounting Officer
Ms. Helena Kyttari Djupesland
Co-Founder of Optinose AS (Norway) & Co-Chief Executive Officer of Optinose AS (Norway)
Mr. John Messina
Senior Vice President of Clinical Devel. & Medical Affairs
Dr. Ramy A. Mahmoud M.D., M.P.H.
Chief Executive Officer & Director
Mr. Anthony J. Krick
Vice President & Chief Accounting Officer

How OPTN did perform over past 52-week?

OPTN's closing price is 99.38% higher than its 52-week low of $4.82 where as its distance from 52-week high of $20.03 is -52.06%.

How many employees does OPTN have?

Number of OPTN employees currently stands at 127.

Link for OPTN official website?

Official Website of OPTN is: https://www.optinose.com

How do I contact OPTN?

OPTN could be contacted at phone 267 364 3500 and can also be accessed through its website. OPTN operates from 1020 Stony Hill Road, Yardley, PA 19067, United States.

How many shares of OPTN are traded daily?

OPTN stock volume for the day was 811.06K shares. The average number of OPTN shares traded daily for last 3 months was 119.12K.

What is the market cap of OPTN currently?

The market value of OPTN currently stands at $97.22M with its latest stock price at $9.60 and 10.13M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	127
Beta	-0.89
Sales or Revenue	$70.99M
5Y Sales Change%	2.565%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

OPTN Company Profile and Key Details

OptiNose

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways